Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $3

Benzinga · 1d ago
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $3.5 to $3.